{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:51:17Z","timestamp":1761871877971,"version":"build-2065373602"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.clml.2021.10.003","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T06:25:50Z","timestamp":1634624750000},"page":"e261-e268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["CAR-T in B-Cell Lymphomas: The Past, Present, and Future"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8359-0178","authenticated-orcid":false,"given":"Taha","family":"Al-Juhaishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.10.003_bib0001","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11899-021-00615-7","article-title":"Selecting the optimal CAR-T for the treatment of B-cell malignancies","volume":"1","author":"Al-Juhaishi","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"issue":"16","key":"10.1016\/j.clml.2021.10.003_bib0002","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.10.003_bib0003","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/14656566.2019.1582643","article-title":"Choosing the right pharmacotherapy for non-Hodgkin's lymphoma: does one size fit all?","volume":"20","author":"Al Juhaishi","year":"2019","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clml.2021.10.003_bib0004","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1080\/14656566.2020.1727445","article-title":"Perspectives on chemotherapy for the management of double-hit lymphoma","volume":"21","author":"Al-Juhaishi","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clml.2021.10.003_bib0005","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","article-title":"Diffuse large B-cell lymphoma","volume":"87","author":"Martelli","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2021.10.003_bib0006","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.bbmt.2016.04.019","article-title":"Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma: increasingly successful application to older patients","volume":"9","author":"Fenske","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.10.003_bib0007","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.bbmt.2019.12.771","article-title":"Cellular immunotherapy for refractory diffuse large B cell lymphoma in the chimeric antigen receptor-engineered T cell era: still a role for allogeneic transplantation?","volume":"4","author":"Dreger","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.10.003_bib0008","unstructured":"FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-car-t-cell-therapy-treat-adults-certain-types-large-b-cell-lymphoma"},{"key":"10.1016\/j.clml.2021.10.003_bib0009","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.10.003_bib0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"1","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.10.003_bib0011","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.10.003_bib0012","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.10.003_bib0013","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.10.003_bib0014","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"27","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.10.003_bib0015","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy","volume":"7","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.10.003_bib0016","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood.2019001694","article-title":"Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma","volume":"134","author":"Frigault","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.10.003_bib0017","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/bloodadvances.2020004106","article-title":"CD19 directed CAR T cell therapy for treatment of primary CNS lymphoma","volume":"20","author":"Siddiqi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.10.003_bib0018","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.10.003_bib0019","unstructured":"FDA grants accelerated approval to axicabtagene ciloleucel for relapsed or refractory follicular lymphoma. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-grants-accelerated-approval-axicabtagene-ciloleucel-relapsed-or-refractory-follicular-lymphoma Accessed January 5, 2021."},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.10.003_bib0020","first-page":"40","article-title":"Primary analysis of Zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL)","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.10.003_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-6367(21)00095-6","article-title":"Primary analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with relapsed\/refractory (R\/R) indolent non-Hodgkin lymphoma (iNHL)","volume":"27","author":"Jacobson","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"10.1016\/j.clml.2021.10.003_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-138983","article-title":"Efficacy and safety of tisagenlecleucel in adult patients with relapsed\/refractory follicular lymphoma: interim analysis of the phase 2 Elara trial","volume":"136","author":"Fowler","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.10.003_bib0023","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-021-01288-9","article-title":"ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma","author":"Munshi","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.10.003_bib0024","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"suppl_1","key":"10.1016\/j.clml.2021.10.003_bib0025","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1182\/blood-2019-124750","article-title":"Post-marketing use outcomes of an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (Axi-Cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US)","volume":"134","author":"Pasquini","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.10.003_bib0026","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.10.003_bib0027","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/bjh.16155","article-title":"Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy","volume":"187","author":"Hashmi","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.10.003_bib0028","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.10.003_bib0029","first-page":"3776","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"15","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.10.003_bib0030","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.3324\/haematol.2020.254045","article-title":"Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma","volume":"10","author":"Strati","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.10.003_bib0031","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1016\/j.bbmt.2018.12.311","article-title":"Cytopenias after chimeric antigen receptor T-cells (CAR-T) infusion; patterns and outcomes","volume":"25","author":"Schaefer","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2021.10.003_bib0032","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1080\/10428194.2019.1697814","article-title":"Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)","volume":"61","author":"Nahas","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.10.003_bib0033","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.10.003_bib0034","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"19","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2021.10.003_bib0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2019.12.002","article-title":"Mechanisms of resistance to CAR T cell therapies","volume":"65","author":"Singh","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.clml.2021.10.003_bib0036","first-page":"372","article-title":"Mechanisms of resistance to CAR T cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2021.10.003_bib0037","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"10","author":"Orlando","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2021.10.003_bib0038","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"20","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.10.003_bib0039","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"5","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2021.10.003_bib0040","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1158\/2159-8290.CD-18-1314","article-title":"Na\u00efve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers","volume":"4","author":"Das","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2021.10.003_bib0041","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"2","author":"Fenske","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.10.003_bib0042","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell\u2013engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"18","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.10.003_bib0043","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clml.2021.10.003_bib0044","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1002\/acg2.86","article-title":"Toward \u201coff-the-shelf\u201d allogeneic CAR T cells","volume":"3","author":"Aftab","year":"2020","journal-title":"Adv Cell Gene Ther"},{"key":"10.1016\/j.clml.2021.10.003_bib0045","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3390\/jcm8101702","article-title":"NK cell-based immunotherapy for hematological malignancies","volume":"8","author":"Sivori","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.clml.2021.10.003_bib0046","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.canlet.2019.11.033","article-title":"CAR-NK for tumor immunotherapy: clinical transformation and future prospects","volume":"472","author":"Wang","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.clml.2021.10.003_bib0047","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering natural killer cells for cancer immunotherapy","volume":"8","author":"Rezvani","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.clml.2021.10.003_bib0048","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.10.003_bib0049","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.10.003_bib0050","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1182\/blood-2013-08-519413","article-title":"Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation","volume":"122","author":"Kochenderfer","year":"2013","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.clml.2021.10.003_bib0051","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2020.38.15_suppl.8002","article-title":"First-in-human data of ALLO-501 and ALLO-647 in relapsed\/refractory large B-cell or follicular lymphoma (R\/R LBCL\/FL): ALPHA study","volume":"38","author":"Neelapu","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.10.003_bib0052","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","article-title":"Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial","volume":"26","author":"Shah","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2021.10.003_bib0053","first-page":"1632","article-title":"Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma","volume":"136","author":"Tong","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.10.003_bib0054","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"2","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.10.003_bib0055","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2352-3026(20)30120-4","article-title":"Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial","volume":"7","author":"Kalakonda","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2021.10.003_bib0056","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"7","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2021.10.003_bib0057","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021023831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021023831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:39:03Z","timestamp":1761871143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021023831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S2152265021023831"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.10.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T in B-Cell Lymphomas: The Past, Present, and Future","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}